Literature DB >> 11170985

Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997.

M McBean1, S Rajamani.   

Abstract

Rates of hospitalization due to septicemia (International Classification of Diseases, Ninth Revision, Clinical Modification, code 038) in the US elderly population for 1986-1997 were examined, using Medicare administrative data. Age group-, sex-, and race-adjusted rates more than doubled from 1986 through 1997, from 3.42 to 7.42 per 1000 beneficiaries. The 1997 rates of septicemia increased with age, from 4.47 per 1000 beneficiaries among persons 65-74 years old to 18.1 per 1000 beneficiaries among persons > or =85 years old. The rates of septicemia were slightly greater among men (7.46 per 1000 beneficiaries) than among women (7.39 per 1000 beneficiaries) and were higher among blacks (13.61 per 1000 beneficiaries) than among whites (6.89 per 1000 beneficiaries). The most likely sites of the origin of the septicemia were the urinary tract (40.1%) and lungs (15.3%). Escherichia coli and Staphylococcus species were the most frequently reported organisms. Diabetes was listed as a comorbidity in 24.5% of the hospitalizations. We estimate that the cost to Medicare for septicemia hospitalizations in 1997 was >$1.8 billion.

Entities:  

Mesh:

Year:  2001        PMID: 11170985     DOI: 10.1086/318526

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

Review 1.  Covert operations of uropathogenic Escherichia coli within the urinary tract.

Authors:  Jean M Bower; Danelle S Eto; Matthew A Mulvey
Journal:  Traffic       Date:  2005-01       Impact factor: 6.215

2.  Usefulness of blood cultures in the management of febrile patients in long-term care facilities.

Authors:  R Raz; Y Ben-Israel; D Gronich; E Granot; R Colodner; I Visotzky
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-11       Impact factor: 3.267

3.  A killed, genetically engineered derivative of a wild-type extraintestinal pathogenic E. coli strain is a vaccine candidate.

Authors:  Thomas A Russo; Janet M Beanan; Ruth Olson; Stacy A Genagon; Ulrike MacDonald; John J Cope; Bruce A Davidson; Brian Johnston; James R Johnson
Journal:  Vaccine       Date:  2007-02-05       Impact factor: 3.641

4.  Effect of inactivation of the global oxidative stress regulator oxyR on the colonization ability of Escherichia coli O1:K1:H7 in a mouse model of ascending urinary tract infection.

Authors:  James R Johnson; Connie Clabots; Henry Rosen
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Defining Sepsis Mortality Clusters in the United States.

Authors:  Justin Xavier Moore; John P Donnelly; Russell Griffin; George Howard; Monika M Safford; Henry E Wang
Journal:  Crit Care Med       Date:  2016-07       Impact factor: 7.598

6.  Effect of nosocomial bloodstream infections on mortality, length of stay, and hospital costs in older adults.

Authors:  Keith S Kaye; Dror Marchaim; Ting-Yi Chen; Timothy Baures; Deverick J Anderson; Yong Choi; Richard Sloane; Kenneth E Schmader
Journal:  J Am Geriatr Soc       Date:  2014-01-17       Impact factor: 5.562

7.  Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges.

Authors:  S E Beekmann; D J Diekema; K C Chapin; G V Doern
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

Review 8.  Economic aspects of severe sepsis: a review of intensive care unit costs, cost of illness and cost effectiveness of therapy.

Authors:  Hilmar Burchardi; Heinz Schneider
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 9.  Th17 cytokines and the gut mucosal barrier.

Authors:  Christoph Blaschitz; Manuela Raffatellu
Journal:  J Clin Immunol       Date:  2010-02-02       Impact factor: 8.317

10.  The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.

Authors:  Thomas A Russo; Catherine D McFadden; Ulrike B Carlino-MacDonald; Janet M Beanan; Ruth Olson; Gregory E Wilding
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.